Rambam MedTech
Technology Transfer at Rambam
Rambam MedTech Ltd. is the technology transfer company (TTC) for Rambam Health Care Campus. Since 2014, it has served as the liaison between Rambam’s research community and industry by facilitating the process of bringing medical innovations to the market.
Rambam MedTech Ltd. is authorized by the Israeli government to handle all innovations and intellectual property (IP) generated by Rambam clinicians and scientists. As such, the company supports the pioneering and innovative research carried out by Rambam’s physicians and researchers, and regularly helps transform ideas into groundbreaking medical products.
Rambam's topnotch medical professionals are constantly challenged by unmet clinical needs which lead them to develop innovations. Examples include cardiovascular, orthopedic, surgical, ophthalmic and endoscopic devices; stem cell technologies; and precision personalized medicine, among many others.Rambam MedTech promotes and encourages creative thinking and ideation within the Rambam community and serves as a bridge between Rambam and the Biotech industry. Its professional team assists the inventors throughout the process: developing innovative ideas, filing patent applications, securing funding for nitial development, and commercializing the IP through licensing to experienced business affiliates or by the formation of spin-off companies.
Prior to his current position as the CEO of MedTech, Dr. Atlas headed the National Institute for Biotechnology in the Negev Ltd. (NIBN), an incubator at Ben-Gurion University in the Negev. The incubator’s activities focused on pre-clinical development of pharmaceutical and biopharmaceutical drugs for indications such as cancer, autoimmunity, neurodegeneration, metabolism, and more. At NIBN, Dr. Atlas gained experience in advancing pre-clinical development programs for small molecules and biopharmaceuticals. In addition, he led the Intellectual Property and business aspects of the Incubator. Prior to that role, Dr. Atlas served as CEO of a biotech startup company in the field of pain management for dentistry applications. Before that, he was a project manager at Omrix Biopharmaceuticals (a J&J company), in charge of pre-clinical development of tissue regeneration applications for Omrix's Fibrin technology.
Dr. Atlas studied molecular biology and completed a Ph.D. degree at the Weizmann Institute of Science in 2005, followed by a postdoc at Columbia University Medical School, New York.
Ms. Shmuel is the assistant to the CEO at Rambam MedTech. She is responsible for promoting innovation among the Rambam Health Care Campus staff; organizing conferences and seminars, managing the hospital’s patent portfolio, and establishing contacts with contract research organizations. Ms. Shmuel has eight years of experience managing departments in large companies and law firms. She completed her LL.M at the University of Haifa.
Ronen Kahana
Ronen Kahana is the director of business development at Rambam MedTech. Prior to that role, he founded and headed a unique pharmaceutical startup company that developed novel drugs for endogenous recovery of bone marrow and blood parameters. In the past, he innovated novel anti-viral applications, co-founded a biotech startup company centered on anti-viral management in humans and animals, and worked at the Kimron Veterinary Institute in the field of vaccine control, where he developed and implemented new technologies and established Crucell’s PER.C6® technology. Mr. Kahana holds an M.Sc. in industrial biotechnology from Bar-Ilan University.